Irish research cuts threaten economic recovery
As Ireland officially emerges from its worst recession for 70 years, the government's commitment to reduce its economic reliance on tourism and agriculture and to develop a knowledge-based 'smart economy' is in peril. The threat comes from cuts in public-sector research funding and from the rationalization of scientific industry, notably in the pharmaceutical sector.
It was revealed in July that some 950 graduate student and postdoctoral research positions, crucial to the development of Ireland's smart economy, will be lost this year (see go.nature. com/3tXbVU). These posts represent a 33% cut in just two years in the number of researchers funded by Science Foundation Ireland (SFI), a state body entrusted with the implementation of the government's strategy for science, technology and innovation. Last year, the SFI's budget for new researchers dropped by 80% from the previous year, and the trend is set to continue (Nature 463, 410-411; 2010).
Ireland's researchers are not alone in such experiences, but it
Games and play mean different things in an educational context
In discussing the importance of computer games for conveying serious messages through play, Aleks Krotoski uses "play" and "games" interchangeably (Nature 466, 695; 2010). However, this is incorrect in the context of human development: these terms denote separate constructs, with different ontogenies, proximal causes and functions.
Play is mainly a behaviour of juveniles and is not functional in its immediate environment; its benefits relate to creativity and novelty. Games are developed later in childhood and are governed by rules based on deduction; their benefits tend to be specific to the game's dimensions (such as hand-eye coordination). What Krotoski is alarming that the cuts come at a time when multinational drug companies are undergoing largescale rationalization of their global workforces. The country has long been a hub for this sector because of its major tax incentives, good infrastructure and pool of talent.
Numbers of job losses are in the thousands as a result of recent acquisitions. For example, 18% of Pfizer's cuts this year of 6,000 jobs worldwide were in Ireland. The country is being displaced by emerging economies such as those of India and the Far East, where costs are low.
The Irish government needs to reposition itself as a major player in this area by re-evaluating its commitment to research funding and to attracting foreign investment. Reviving the smart economy will improve the prospects of thousands of Irish scientists and engineers currently staring into the abyss of unemployment and emigration.
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As counsel for the researcher plaintiffs in the lawsuit against the US National Institutes of Health (NIH) on experiments using human embryonic stem cells, I write to correct your assertion that the progress of the suit poses a threat to "the very framework of federal funding for science" (Nature 466, 159; 2010).
As the US District Court for the District of Columbia held on 23 August (go.nature. com/1z6f5K), federal funding for embryonic stem-cell research violates Congress's prohibition against federal funding for "research in which a human embryo or embryos are destroyed, discarded, or knowingly subjected to risk of injury or death".
In its decision in June that the researcher plaintiffs had sufficient standing to challenge the NIH guidelines for human embryonic stem-cell research, the Court of Appeals did not suggest that researchers are "legally entitled to a certain portion of the funding pie" or "that changes in a federal agency's research priorities … open the agency up to lawsuits". Instead, the court faithfully applied a long line of cases, stretching back to the early 1970s. These consistently held that participants in regulated markets suffer injury when illegal changes in the regulatory scheme alter the competitive landscape -in this case, the increased competition for funding to support research on adult (as opposed to embryonic) stem cells. None of those cases invited runaway litigation against federal agencies, and the court in this case extended no such invitation.
What's more, the NIH deemed as "unresponsive to the issues at hand" many of the comments it received on its draft guidelines, which were opposed to the federal funding of human embryonic stem-cell research (see go.nature. com/nVJy5f 
